Guillain-Barre Syndrome Global Market Report 2025

The guillain-barre syndrome market size has grown strongly in recent years. It will grow from $0.6 billion in 2024 to $0.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the increasing demand for GBS treatments, a rise in viral infections, expanding global vaccination campaigns, a better understanding of autoimmune mechanisms, and greater awareness and diagnosis.

The guillain-barre syndrome market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The projected growth in the forecast period is driven by the rising prevalence of Guillain-Barré syndrome, the growing impact of climate change, the expanding use of immunotherapies and drugs, improved diagnostic capabilities, and the increasing occurrence of multifocal motor neuropathy. Key trends expected in this period include advancements in diagnostic techniques, the development of immunoglobulin therapies, enhancements in plasmapheresis methods, exploration of gene therapy, a stronger focus on early intervention, the identification of novel biomarkers for prognosis, and the expansion of clinical trials for innovative treatments.

The rising prevalence of immunological diseases is expected to drive the growth of the Guillain-Barré syndrome market. Immunological diseases occur when the immune system is either overactive, underactive, or misdirected, leading to conditions such as autoimmune disorders, allergies, or immunodeficiencies. The increase in these diseases is influenced by factors such as environmental changes, lifestyle habits, improved diagnostic capabilities, and genetic predisposition. Guillain-Barré syndrome can develop as a result of an autoimmune response in which the body’s immune system mistakenly attacks the peripheral nerves, causing inflammation and nerve damage. For example, in July 2024, a report from the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, revealed that by the end of 2022, around 39.5 million people worldwide were living with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths that year. By 2023, the global number of people living with HIV had increased to approximately 39.9 million. Consequently, the growing risk of immunological diseases is fueling the Guillain-Barré syndrome market.

Leading companies in the Guillain-Barré syndrome market are focusing on developing innovative therapies, such as monoclonal antibodies, to enhance treatment effectiveness, address unmet clinical needs, and strengthen their market presence. Monoclonal antibodies are lab-engineered proteins designed to target specific antigens, helping regulate immune responses and improve therapeutic results. For instance, in October 2023, Annexon Inc., a US-based biopharmaceutical company, received orphan drug designation from the European Medicines Agency (EMA) for its drug ANX005, developed for the treatment of Guillain-Barré syndrome. ANX005 is a monoclonal antibody targeting C1q, showing early improvements in muscle strength and a reduced need for ventilation compared to IVIg, representing a significant advancement in treatment options.

In July 2022, ArchiMed SAS, a France-based investment company specializing in the healthcare industry, acquired Natus Medical Incorporated for $1.1 billion. This acquisition aims to strengthen ArchiMed SAS’s position in neurodiagnostic devices while expanding its healthcare portfolio. By leveraging Natus' expertise and product offerings, the company seeks to drive innovation and growth in the neurodiagnostic sector. Natus Medical Incorporated, a US-based medical device company, focuses on designing and manufacturing medical devices for screening, diagnosing, and treating neurological disorders.

Major players in the guillain-barre syndrome market are Pfizer Inc., Roche AG, Thermo Fisher Scientific Inc., AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., Annexon Inc., Immunovant Inc., CSL Behring LLC, Hansa Biopharma AB, NeuLine Health Inc., Ridge Diagnostics Inc., Deymed Diagnostic LLC, and VYVGART Hytrulo.

North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in guillain-barre syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the guillain-barre syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Guillain-Barré syndrome is a rare neurological condition in which the body's immune system mistakenly targets the peripheral nervous system. This results in muscle weakness, numbness, tingling, and, in severe cases, paralysis. While the exact cause remains unknown, it is often triggered by infections, such as respiratory or gastrointestinal infections, and occasionally by vaccinations or surgery.

The primary types of Guillain-Barré syndrome include acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Miller Fisher syndrome (MFS), acute motor axonal neuropathy (AMAN), among others. AIDP is an autoimmune condition in which the immune system attacks the myelin sheaths of peripheral nerves, leading to inflammation and demyelination. Treatment options for GBS include intravenous immunoglobulin (IVIG), plasma exchange, and other therapies. These treatments are primarily administered through parenteral and oral routes. The condition is managed in various healthcare settings, such as hospitals, clinics, diagnostic centers, and other medical facilities.

The guillain-barre syndrome market research report is one of a series of new reports that provides guillain-barre syndrome market statistics, including the guillain-barre syndrome industry's global market size, regional shares, competitors with a guillain-barre syndrome market share, detailed guillain-barre syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the guillain-barre syndrome industry. This guillain-barre syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The guillain-barre syndrome market consists of revenues earned by entities by providing services such as plasma exchange (plasmapheresis), intravenous immunoglobulin (IVIG) therapy, neurological diagnostic tests, and supportive care treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The guillain-barre syndrome market also includes sales of pharmaceutical drugs, immunotherapies, and diagnostic tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.